Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS‐CoV‐2 infection in vitro

6 Apr 2021

Abstract excerpt

BACKGROUND AND PURPOSE: The SARS-COV-2 pandemic and the global spread of coronavirus disease 2019 (COVID-19) urgently call for efficient and safe antiviral treatment strategies. A straightforward approach to speed up drug development at lower costs is drug repurposing. Here, we investigated the therapeutic potential of targeting the interface of SARS CoV-2 with the host via repurposing of clinically licensed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemical Reactions and Isotopes
Share to Long-Term Effects of COVID-19
Share to Pharmacological Receptor Mechanisms and Effects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33825201
DOI: 10.1111/bph.15418

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS‐CoV‐2 infection in vitroPMID 33825201Read ↗

Synergism between remdesivir and ribavirin leads to SARS‐CoV‐2 extinction in cell cultureSemantic proximity Read ↗

Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium <i>in vitro</i>Semantic proximity Read ↗

Identification of Broad Anti-Coronavirus Chemical Agents for Repurposing Against SARS-CoV-2 and Variants of ConcernSemantic proximity Read ↗

Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2Semantic proximity Read ↗

Identification of novel antiviral drug combinations in vitro and tracking their developmentSemantic proximity Read ↗

Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitroSemantic proximity Read ↗

Simeprevir Potently Suppresses SARS-CoV‑2 Replication and Synergizes with RemdesivirSemantic proximity Read ↗

The FDA-approved drug cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replicationSemantic proximity Read ↗

Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)Semantic proximity Read ↗

SARS-CoV-2 infection enhancement by Amphotericin B: Implications for disease managementSemantic proximity Read ↗

Antiviral Activity of Micafungin and Its Derivatives against SARS-CoV-2 RNA ReplicationSemantic proximity Read ↗

<i>In vitro</i> efficacy of Artemisinin-based treatments against SARS-CoV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.